Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMRX 
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.07% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.00B USD | Price to earnings Ratio 955 | 1Y Target Price 12 |
Price to earnings Ratio 955 | 1Y Target Price 12 | ||
Volume (30-day avg) 4 | Beta 1.12 | 52 Weeks Range 6.68 - 9.79 | Updated Date 08/28/2025 |
52 Weeks Range 6.68 - 9.79 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.17 | Actual 0.25 |
Profitability
Profit Margin 0.12% | Operating Margin (TTM) 15.46% |
Management Effectiveness
Return on Assets (TTM) 6.85% | Return on Equity (TTM) -881.26% |
Valuation
Trailing PE 955 | Forward PE 6.3 | Enterprise Value 5450131332 | Price to Sales(TTM) 1.05 |
Enterprise Value 5450131332 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 9.33 | Shares Outstanding 314079008 | Shares Floating 168726546 |
Shares Outstanding 314079008 | Shares Floating 168726546 | ||
Percent Insiders 46.51 | Percent Institutions 45.92 |
Upturn AI SWOT
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview
History and Background
Amneal Pharmaceuticals, Inc. was founded in 2002 by Chirag and Chintu Patel. It grew through organic expansion and strategic acquisitions to become a significant player in the generic pharmaceutical industry. Amneal is focused on developing, manufacturing, and distributing a diverse range of generic and specialty pharmaceutical products.
Core Business Areas
- Generics: Develops, manufactures, and markets a wide range of generic pharmaceutical products across various therapeutic areas.
- Specialty: Focuses on developing and marketing differentiated pharmaceutical products, including injectables and complex dosage forms.
Leadership and Structure
Nir Patel serves as the CEO. The organizational structure consists of functional departments such as R&D, manufacturing, commercial operations, and finance, overseen by a board of directors.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals: Amneal offers a broad portfolio of generic medications. Market share varies by product. Competitors: Teva, Mylan, Sandoz.
- Injectables: Specialty injectables used in hospitals and clinics. Competitors: Fresenius Kabi, Pfizer.
- Complex Dosage Forms: Oral solids and liquids with complex formulations. Competitors: Lannett, Endo.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. The generics market is driven by patent expirations and cost-containment pressures, while the specialty market focuses on high-value, differentiated products.
Positioning
Amneal positions itself as a diversified pharmaceutical company with a focus on both generic and specialty products. Its competitive advantage lies in its vertically integrated manufacturing capabilities and its ability to develop and commercialize complex generics and specialty products.
Total Addressable Market (TAM)
The global generics market is estimated to be hundreds of billions of dollars. The global injectables market is estimated to be ~$100 billion. Amneal captures a portion of this large market, focusing on specific therapeutic areas and dosage forms.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Vertically integrated manufacturing
- Strong R&D capabilities
- Experienced management team
Weaknesses
- High debt levels
- Exposure to pricing pressures
- Dependence on key products
- Regulatory risk
Opportunities
- New product launches
- Strategic acquisitions
- Expansion into new markets
- Increasing demand for generics
Threats
- Intense competition
- Patent expirations
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Viatris Inc. (VTRS)
- Lannett Company, Inc. (LCI)
Competitive Landscape
Amneal faces intense competition from established generic pharmaceutical companies. It competes on price, product quality, and service. Amneal's strengths lie in its diversified product portfolio and vertically integrated manufacturing.
Major Acquisitions
Actavis plc (some products)
- Year: 2017
- Acquisition Price (USD millions): 3175
- Strategic Rationale: Expand product portfolio and market share in the generics market.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by acquisitions and new product launches, but has been offset by pricing pressures and competition.
Future Projections: Analyst estimates suggest moderate revenue growth in the coming years, driven by new product launches and market share gains. Profitability is expected to improve as the company reduces debt and improves operational efficiency.
Recent Initiatives: Recent initiatives include streamlining operations, reducing debt, and focusing on high-value products.
Summary
Amneal Pharmaceuticals is a diversified pharmaceutical company with both generic and specialty products and has shown reasonable growth, and diversified product portfolio and vertically integrated manufacturing and its high debt level and profitability and pricing pressures and needs to continue focus on debt reduction and operational improvements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Investor presentations
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and a thorough understanding of the risks involved.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Exchange NYSE | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2009-01-15 | Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8300 | Website https://www.amneal.com |
Full time employees 8300 | Website https://www.amneal.com | ||
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.